Cytek Biosciences Reports Second Quarter 2026 Financial Results
Rhea-AI Summary
Cytek Biosciences (Nasdaq: CTKB) reported second quarter 2026 revenue of $48.1 million, up 6% year over year, driven by instrument growth in the U.S. and China and higher service revenue. GAAP gross profit rose 19% to $28.3 million, with gross margin improving to 59% (53% excluding a one-time tariff refund). Non-GAAP adjusted gross margin was 61% (56% excluding the refund).
Total recurring revenue reached $18.5 million, and on a trailing 12‑month basis represented 35% of total revenue, up from 32% a year earlier. The installed base expanded to 3,933 instruments, adding 142 units in the quarter. Operating expenses rose 15% to $39.7 million, including higher R&D, sales and marketing, and a 24% increase in G&A tied to litigation-related expenses, severance and personnel costs. Net loss widened to $12.2 million, or $0.09 per share, versus $5.6 million a year ago, and adjusted EBITDA shifted to a $1.5 million loss.
Cash, cash equivalents and marketable securities totaled $262.0 million at June 30, 2026. Cytek launched the Cytek Borealis 7‑laser full spectrum flow cytometer and new Cytek Aurora Evo configurations. The company updated 2026 revenue guidance to $207–$212 million, raising the midpoint by $1 million, assuming unchanged foreign exchange rates.
Positive
- Revenue +6% YoY to $48.1 million in Q2 2026
- GAAP gross margin improved to 59% from 52% year over year
- Adjusted gross margin increased to 61% from 56% year over year
- Recurring revenue $18.5 million; 35% of TTM revenue vs 32% prior year
- Installed base grew to 3,933 instruments, adding 142 units in Q2 2026
- 2026 revenue guidance raised midpoint to $209.5 million (range $207–$212 million)
- Liquidity remained strong with $262.0 million in cash, equivalents and marketable securities
Negative
- Net loss widened to $12.2 million from $5.6 million in Q2 2025
- Operating loss increased to $11.4 million from $10.6 million year over year
- Adjusted EBITDA turned to a $1.5 million loss from $1.3 million positive
- Operating expenses rose 15% to $39.7 million year over year
- G&A expenses increased 24% to $16.8 million due to litigation, severance and personnel costs
- Accumulated deficit expanded to $132.8 million as of June 30, 2026
News Explained
At June 30, liquidity was $262.0 million versus $262.2 million in March, while reported common shares were higher than at year-end.
Cytek Biosciences reported completed second-quarter results for the period ended
The company reported
Market Reaction – CTKB
Following this news, CTKB has gained 0.48%, reflecting a mild positive market reaction. Our momentum scanner has triggered 2 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $4.20.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FREMONT, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the second quarter ended June 30, 2026.
Recent Highlights
- Total revenue for the second quarter of 2026 was
$48.1 million , representing a6% increase compared to the second quarter of 2025 - Launched Cytek Borealis™, a new 7-laser full spectrum flow cytometer with new and proprietary reagents enabling high-resolution 60-color panels
- Introduced Cytek Aurora™ Evo instrument configurations with expanded automation capabilities for highly automated lab environments
- Total recurring revenue, comprised of service and reagent revenues, reached
$18.5 million in the second quarter. On a trailing-12-month basis, recurring revenue represented35% of total revenue, up from32% on a trailing-12-month basis as of the second quarter of 2025 - Expanded to a total installed base of 3,933 Cytek instruments, adding 142 units in the second quarter of 2026
- Updates full year 2026 total revenue guidance to
$207 million to$212 million , raising the midpoint by$1 million
“Our second quarter results reflect continued execution against our strategic priorities, exemplified by strong double-digit revenue growth in instruments in the U.S. and in China and ongoing and consistent expansion of our service business,” said Wenbin Jiang, CEO of Cytek Biosciences. “Looking ahead, our priorities remain clear: accelerating adoption of our instrument platforms, including newly launched instruments, expanding recurring revenue business and extending our technology leadership. We believe our investments in products, people, and operations position Cytek well for the remainder of 2026 and the long-term opportunity ahead.”
Second Quarter 2026 Financial Results
Total revenue for the second quarter of 2026 was
GAAP gross profit was
Operating expenses were
Research and development expenses were
Sales and marketing expenses were
General and administrative expenses were
Loss from operations in the second quarter of 2026 was
Adjusted EBITDA loss in the second quarter of 2026 was
Cash, cash equivalents and marketable securities totaled
2026 Outlook
Cytek Biosciences is updating its revenue outlook for the full year 2026 to be in the range of
Webcast Information
Cytek will host a conference call to discuss its second quarter 2026 financial results on Wednesday, August 5, 2026, at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A webcast of the conference call can be accessed at investors.cytekbio.com.
About Cytek Biosciences, Inc.
Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling™ (FSP®) technology. Cytek’s novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with precision and sensitivity. Cytek’s platform includes: its core FSP instruments, the Cytek Aurora™, Northern Lights™, Cytek Aurora™ CS and Cytek Aurora™ Evo systems; the Cytek Orion™ reagent cocktail preparation system; the Enhanced Small Particle™ (ESP™) detection technology; the flow cytometers and imaging products under the Amnis® and Guava® brands; and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe. More information about the company and its products is available at www.cytekbio.com.
Cytek’s products are for research use only and not for use in diagnostic procedures (other than Cytek’s Northern Lights-CLC system and certain reagents, which are available for clinical use only in China and the European Union).
Cytek, Full Spectrum Profiling, FSP, Cytek Aurora, Cytek Borealis, Northern Lights, Enhanced Small Particle, ESP, Cytek Orion, Amnis and Guava are trademarks of Cytek Biosciences, Inc.
In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Cytek uses its website (www.cytekbio.com), LinkedIn page and X account as channels of distribution for information about the company, its products, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Certain information disseminated through these channels may be material to investors, and Cytek may use these channels to disseminate such information in accordance with Regulation FD and other applicable disclosure requirements. Therefore, investors should monitor Cytek’s website, LinkedIn page, and X account in addition to following its SEC filings, news releases, public conference calls and webcasts.
Statement Regarding Use of Non-GAAP Financial Information
Cytek has presented certain financial information in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”) and also on a non-GAAP basis for the three-month period ended June 30, 2026 and June 30, 2025. Management believes that non-GAAP financial measures, including “Adjusted gross profit,” “Adjusted gross profit margin,” “Adjusted EBITDA” and “Adjusted EBITDA excluding investment income,” referenced in this release, taken in conjunction with GAAP financial measures, provide useful information for both management and investors by excluding certain non-cash and other expenses that are not indicative of the company’s core operating results. Management uses non-GAAP measures to compare the company’s performance relative to forecasts and strategic plans and to benchmark the company’s performance externally against competitors. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of the company’s operating results as reported under U.S. GAAP. Cytek encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business. Reconciliations between GAAP and non-GAAP operating results are presented in the accompanying tables of this release.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, without limitation, statements regarding Cytek’s business strategies, market opportunities, product plans and expectations, and continued investment in its products, people, and infrastructure; Cytek’s expanding installed base and future recurring revenue growth in its service and reagent businesses; and Cytek’s future financial performance, including its outlook for fiscal year 2026 and expectations for 2026 total revenue. These statements are based on management’s current expectations, forecasts, beliefs, assumptions and information currently available to management. These statements also deal with future events and involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In addition, new risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements. Factors that could cause actual results to differ materially include global geopolitical, economic and market conditions; Cytek’s ability to manage the impacts of recent and future export controls and licensing requirements, tariffs and NIH funding policies on its business; Cytek’s ability to evaluate its prospects for future viability and predict future performance; Cytek’s ability to accurately forecast customer demand and adoption of its products; Cytek’s ability to recognize the anticipated benefits of collaborations; Cytek’s dependence on certain sole and single source suppliers; competition; market acceptance of Cytek’s current and potential products; Cytek’s ability to manage the growth and complexity of its organization, maintain relationships with customers and suppliers and hire and retain key employees; Cytek’s ability to manufacture its products in high-quality commercial quantities successfully and consistently to meet demand; Cytek’s ability to increase penetration in its existing markets and expand into adjacent markets; Cytek’s ability to secure additional distributors or maintain good relationships with its existing distributors; Cytek’s ability to successfully develop and introduce new products; Cytek’s ability to maintain, protect and enhance its intellectual property; Cytek’s ability to continue to stay in compliance with its material contractual obligations, applicable laws and regulations; and foreign currency exchange impacts. You should refer to the section titled “Risk Factors” set forth in Cytek’s most recent Quarterly Report on Form 10-Q filed with the SEC on May 7, 2026, Cytek’s Quarterly Report on Form 10-Q to be filed with the SEC on or about the date hereof and other filings Cytek makes with the SEC from time to time for a discussion of important factors that may cause actual results to differ materially from those expressed or implied by Cytek’s forward-looking statements. Although Cytek believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee that the future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or occur. The forward-looking statements in this press release are applicable only as of the date on which they are made, and Cytek does not assume any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Cytek’s views as of any date subsequent to the date of this press release. Information contained on, or that is referenced or can be accessed through, our website does not constitute part of this document and inclusions of any website addresses herein are inactive textual references only.
Media Contact:
Stephanie Olsen
Lages & Associates
(949) 453-8080
stephanie@lages.com
Investor Contact:
Mark Meehan
Cytek Biosciences
mmeehan@cytekbio.com
| Cytek Biosciences, Inc. Consolidated Balance Sheets (Unaudited) | ||||||||
| (In thousands, except share and per share data) | June 30, 2026 | December 31, 2025 | ||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 73,846 | $ | 90,853 | ||||
| Marketable securities | 188,158 | 170,676 | ||||||
| Trade accounts receivable, net | 49,698 | 62,509 | ||||||
| Inventories | 52,251 | 48,428 | ||||||
| Prepaid expenses and other current assets | 13,978 | 19,530 | ||||||
| Total current assets | 377,931 | 391,996 | ||||||
| Property and equipment, net | 20,801 | 18,009 | ||||||
| Operating lease right-of-use assets | 10,962 | 11,315 | ||||||
| Goodwill | 16,690 | 16,697 | ||||||
| Intangible assets, net | 14,865 | 16,821 | ||||||
| Other noncurrent assets | 5,685 | 6,704 | ||||||
| Total assets | $ | 446,934 | $ | 461,542 | ||||
| Liabilities and stockholders’ equity | ||||||||
| Current liabilities: | ||||||||
| Trade accounts payable | $ | 8,408 | $ | 6,410 | ||||
| Legal settlement liability, current | 2,353 | 2,495 | ||||||
| Accrued expenses | 23,855 | 23,417 | ||||||
| Other current liabilities | 20,513 | 16,978 | ||||||
| Deferred revenue, current | 29,206 | 28,504 | ||||||
| Total current liabilities | 84,335 | 77,804 | ||||||
| Legal settlement liability, noncurrent | 6,368 | 6,786 | ||||||
| Deferred revenue, noncurrent | 18,058 | 18,339 | ||||||
| Operating lease liability, noncurrent | 13,517 | 14,042 | ||||||
| Long-term debt | 246 | 525 | ||||||
| Other noncurrent liabilities | 2,456 | 2,307 | ||||||
| Total liabilities | 124,980 | 119,803 | ||||||
| Stockholders’ equity: | ||||||||
| Common stock, | 130 | 129 | ||||||
| Additional paid-in capital | 451,846 | 441,107 | ||||||
| Accumulated deficit | (132,761 | ) | (101,738 | ) | ||||
| Accumulated other comprehensive income | 2,739 | 2,241 | ||||||
| Total stockholders’ equity | 321,954 | 341,739 | ||||||
| Total liabilities and stockholders’ equity | $ | 446,934 | $ | 461,542 | ||||
| Cytek Biosciences, Inc. Consolidated Statements of Operations and Comprehensive Loss (Unaudited) | ||||||||||||||||
| Three months ended June 30, | Six months ended June 30, | |||||||||||||||
| (In thousands, except share and per share data) | 2026 | 2025 | 2026 | 2025 | ||||||||||||
| Revenue, net: | ||||||||||||||||
| Product | $ | 32,556 | $ | 31,415 | $ | 61,335 | $ | 59,525 | ||||||||
| Service | 15,584 | 14,187 | 30,940 | 27,534 | ||||||||||||
| Total revenue, net | 48,140 | 45,602 | 92,275 | 87,059 | ||||||||||||
| Cost of sales: | ||||||||||||||||
| Product | 12,884 | 14,921 | 28,805 | 30,450 | ||||||||||||
| Service | 6,916 | 6,814 | 13,876 | 12,585 | ||||||||||||
| Total cost of sales | 19,800 | 21,735 | 42,681 | 43,035 | ||||||||||||
| Gross profit | 28,340 | 23,867 | 49,594 | 44,024 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 9,741 | 8,826 | 19,345 | 18,550 | ||||||||||||
| Sales and marketing | 13,174 | 12,134 | 24,820 | 24,643 | ||||||||||||
| General and administrative | 16,825 | 13,531 | 35,292 | 26,429 | ||||||||||||
| Total operating expenses | 39,740 | 34,491 | 79,457 | 69,622 | ||||||||||||
| Loss from operations | (11,400 | ) | (10,624 | ) | (29,863 | ) | (25,598 | ) | ||||||||
| Other income (expense): | ||||||||||||||||
| Interest expense | (281 | ) | (414 | ) | (543 | ) | (705 | ) | ||||||||
| Interest income | 819 | 555 | 1,606 | 1,063 | ||||||||||||
| Other income (expense), net | (781 | ) | 3,708 | (216 | ) | 7,199 | ||||||||||
| Total other income (expense), net | (243 | ) | 3,849 | 847 | 7,557 | |||||||||||
| Loss before income taxes | (11,643 | ) | (6,775 | ) | (29,016 | ) | (18,041 | ) | ||||||||
| Provision for (benefit from) income taxes | 515 | (1,192 | ) | 2,008 | (1,056 | ) | ||||||||||
| Net loss | $ | (12,158 | ) | $ | (5,583 | ) | $ | (31,024 | ) | $ | (16,985 | ) | ||||
| Net loss, basic and diluted | $ | (12,158 | ) | $ | (5,583 | ) | $ | (31,024 | ) | $ | (16,985 | ) | ||||
| Net loss per share, basic | $ | (0.09 | ) | $ | (0.04 | ) | $ | (0.24 | ) | $ | (0.13 | ) | ||||
| Net loss per share, diluted | $ | (0.09 | ) | $ | (0.04 | ) | $ | (0.24 | ) | $ | (0.13 | ) | ||||
| Weighted-average shares used in calculating net loss per share, basic | 129,460,518 | 126,934,294 | 129,084,814 | 127,632,999 | ||||||||||||
| Weighted-average shares used in calculating net loss per share, diluted | 129,460,518 | 126,934,294 | 129,084,814 | 127,632,999 | ||||||||||||
| Comprehensive loss: | ||||||||||||||||
| Net loss | $ | (12,158 | ) | $ | (5,583 | ) | $ | (31,024 | ) | $ | (16,985 | ) | ||||
| Foreign currency translation adjustment, net of tax | 517 | 603 | 845 | 43 | ||||||||||||
| Unrealized loss on marketable securities | (147 | ) | (33 | ) | (348 | ) | (98 | ) | ||||||||
| Net comprehensive loss | $ | (11,788 | ) | $ | (5,013 | ) | $ | (30,527 | ) | $ | (17,040 | ) | ||||
| Cytek Biosciences, Inc. Reconciliation of GAAP to Non-GAAP Measures (Unaudited) | ||||||||||||||||
| Three Months Ended | Six Months Ended | |||||||||||||||
| (In thousands) | June 30, 2026 | June 30, 2025 | June 30, 2026 | June 30, 2025 | ||||||||||||
| GAAP gross profit | $ | 28,340 | $ | 23,867 | $ | 49,594 | $ | 44,024 | ||||||||
| Stock based compensation | $ | 736 | $ | 1,110 | $ | 1,465 | $ | 2,196 | ||||||||
| Amortization of acquisition-related intangible assets | $ | 490 | $ | 481 | $ | 984 | $ | 974 | ||||||||
| Non-GAAP adjusted gross profit | $ | 29,566 | $ | 25,458 | $ | 52,043 | $ | 47,194 | ||||||||
| GAAP gross margin | 59 | % | 52 | % | 54 | % | 51 | % | ||||||||
| Non-GAAP adjusted gross margin | 61 | % | 56 | % | 56 | % | 54 | % | ||||||||
| GAAP net income | $ | (12,158 | ) | $ | (5,583 | ) | $ | (31,024 | ) | $ | (16,985 | ) | ||||
| Depreciation and amortization | $ | 2,985 | $ | 2,988 | $ | 5,797 | $ | 5,869 | ||||||||
| Provision for (benefit from) income taxes | $ | 515 | $ | (1,192 | ) | $ | 2,008 | $ | (1,056 | ) | ||||||
| Interest income | $ | (819 | ) | $ | (555 | ) | $ | (1,606 | ) | $ | (1,062 | ) | ||||
| Interest expense | $ | 281 | $ | 414 | $ | 543 | $ | 705 | ||||||||
| Foreign currency exchange loss (gain) | $ | 729 | $ | (1,593 | ) | $ | 1,881 | $ | (2,871 | ) | ||||||
| Stock based compensation | $ | 5,339 | $ | 6,791 | $ | 10,200 | $ | 13,420 | ||||||||
| Write-off Investment | $ | 1,587 | $ | — | $ | 1,587 | $ | — | ||||||||
| Non-GAAP adjusted EBITDA | $ | (1,541 | ) | $ | 1,270 | $ | (10,614 | ) | $ | (1,980 | ) | |||||
| Investment income | $ | (1,383 | ) | $ | (2,048 | ) | $ | (3,012 | ) | $ | (4,309 | ) | ||||
| Non-GAAP adjusted EBITDA excluding investment income | $ | (2,924 | ) | $ | (778 | ) | $ | (13,626 | ) | $ | (6,289 | ) | ||||
